0000950170-23-068189.txt : 20231205 0000950170-23-068189.hdr.sgml : 20231205 20231205162509 ACCESSION NUMBER: 0000950170-23-068189 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20231204 ITEM INFORMATION: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11 ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231205 DATE AS OF CHANGE: 20231205 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ARCA biopharma, Inc. CENTRAL INDEX KEY: 0000907654 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 363855489 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-22873 FILM NUMBER: 231466931 BUSINESS ADDRESS: STREET 1: 10170 CHURCH RANCH WAY STREET 2: SUITE 100 CITY: WESTMINSTER STATE: CO ZIP: 80021 BUSINESS PHONE: 7209402200 MAIL ADDRESS: STREET 1: 10170 CHURCH RANCH WAY STREET 2: SUITE 100 CITY: WESTMINSTER STATE: CO ZIP: 80021 FORMER COMPANY: FORMER CONFORMED NAME: NUVELO INC DATE OF NAME CHANGE: 20030203 FORMER COMPANY: FORMER CONFORMED NAME: HYSEQ INC DATE OF NAME CHANGE: 19970610 8-K 1 abio-20231204.htm 8-K 8-K
false000090765400009076542023-12-042023-12-04

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 5, 2023 (December 04, 2023)

 

 

ARCA biopharma, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

000-22873

36-3855489

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

10170 Church Ranch Way

Suite 100

 

Westminster, Colorado

 

80021

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (720) 940-2200

 

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common

 

ABIO

 

The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Item 5.08 Shareholder Director Nominations

On December 4, 2023, the board of directors (the “Board”) of ARCA biopharma, Inc., a Delaware corporation, approved January 30, 2024 as the date of the Company’s 2023 Annual Meeting of Stockholders (the “Annual Meeting”). The Board also approved December 6, 2023 as the record date for stockholders entitled to notice of and to vote at the Annual Meeting. Due to the fact that the Annual Meeting will be held more than 30 calendar days from the date of the Company’s 2022 Annual Meeting of Stockholders, the due dates for the provision of any qualified stockholder proposal or qualified stockholder nominations under the rules of the Securities and Exchange Commission (the “SEC”) and the bylaws of the Company listed in the Company’s 2022 Proxy Statement on Schedule 14A as filed with the SEC on November 3, 2022 are no longer applicable. Such nominations or proposals, including any notice on Schedule 14N, are now due to the Company no later than December 11, 2023. The Company currently intends to make its proxy materials available beginning on or about December 19, 2023.

 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number

Description

 

104

Cover Page Interactive Data File. The cover page XBRL tags are embedded within the inline XBRL document (contained in Exhibit 101).

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

 

ARCA biopharma, Inc.
(Registrant)

 

 

 

 

Date:

December 5, 2023

By:

/s/ C. Jeffrey Dekker

 

 

 

Name: C. Jeffrey Dekker
Title: Chief Financial Officer

 

 EX-101.SCH 2 abio-20231204.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 100000 - Document - Document And Entity Information link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 3 abio-20231204_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag City Area Code Document Period End Date Document Type Entity Address, Address Line One Entity Address, Address Line Two Entity Address, City or Town Entity Address, Postal Zip Code Entity Address, State or Province Entity Central Index Key Entity Emerging Growth Company Entity File Number Entity Incorporation, State or Country Code Entity Registrant Name Entity Tax Identification Number Local Phone Number Pre-commencement Issuer Tender Offer Pre-commencement Tender Offer Title of 12(b) Security Security Exchange Name Soliciting Material Trading Symbol Written Communications EX-101.PRE 4 abio-20231204_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Document And Entity Information
Dec. 04, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 04, 2023
Entity Registrant Name ARCA biopharma, Inc.
Entity Central Index Key 0000907654
Entity Emerging Growth Company false
Entity File Number 000-22873
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 36-3855489
Entity Address, Address Line One 10170 Church Ranch Way
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Westminster
Entity Address, State or Province CO
Entity Address, Postal Zip Code 80021
City Area Code (720)
Local Phone Number 940-2200
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common
Trading Symbol ABIO
Security Exchange Name NASDAQ
XML 6 abio-20231204_htm.xml IDEA: XBRL DOCUMENT 0000907654 2023-12-04 2023-12-04 false 0000907654 8-K 2023-12-04 ARCA biopharma, Inc. DE 000-22873 36-3855489 10170 Church Ranch Way Suite 100 Westminster CO 80021 (720) 940-2200 false false false false Common ABIO NASDAQ false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 23 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document And Entity Information Sheet http://www.arcabiopharma.com/20231204/taxonomy/role/DocumentDocumentAndEntityInformation Document And Entity Information Cover 1 false false All Reports Book All Reports abio-20231204.htm abio-20231204.xsd abio-20231204_lab.xml abio-20231204_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 12 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "abio-20231204.htm": { "nsprefix": "abio", "nsuri": "http://www.arcabiopharma.com/20231204", "dts": { "inline": { "local": [ "abio-20231204.htm" ] }, "schema": { "local": [ "abio-20231204.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "abio-20231204_lab.xml" ] }, "presentationLink": { "local": [ "abio-20231204_pre.xml" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 24, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://www.arcabiopharma.com/20231204/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "C_da4ac3ef-017b-4346-bb2c-b0616d647ee4", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "abio-20231204.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "C_da4ac3ef-017b-4346-bb2c-b0616d647ee4", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "abio-20231204.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.arcabiopharma.com/20231204/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.arcabiopharma.com/20231204/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.arcabiopharma.com/20231204/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.arcabiopharma.com/20231204/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.arcabiopharma.com/20231204/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.arcabiopharma.com/20231204/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.arcabiopharma.com/20231204/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.arcabiopharma.com/20231204/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.arcabiopharma.com/20231204/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.arcabiopharma.com/20231204/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.arcabiopharma.com/20231204/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.arcabiopharma.com/20231204/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.arcabiopharma.com/20231204/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.arcabiopharma.com/20231204/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.arcabiopharma.com/20231204/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.arcabiopharma.com/20231204/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.arcabiopharma.com/20231204/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.arcabiopharma.com/20231204/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.arcabiopharma.com/20231204/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.arcabiopharma.com/20231204/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.arcabiopharma.com/20231204/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.arcabiopharma.com/20231204/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.arcabiopharma.com/20231204/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 13 0000950170-23-068189-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000950170-23-068189-xbrl.zip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end